Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Executive Search and Leadership Advisory

Ablynx and AbbVie sign inflammatory disease agreement

Authored by James Sheppard Global pharmaceutical giant AbbVie announced that it had completed the signing of a global licensing agreement with Belgian biotech Ablynx. The agreement will see AbbVie gaining rights to Ablynx’s monoclonal antibody ALX-0061 post completion of phase … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , , , , , , | Leave a comment

Biogen & Amicus partner for new Parkinson’s Drug Hunt

Authored by James Sheppard Biogen IDEC has signed a significant number of partnerships in recent weeks. The latest partnership is with the US based Amicus Therapeutics. Biogen has agreed to fully fund the research and development of Amicus’s Parkinson’s drug … Continue reading

Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , | Leave a comment

Liftstream Life Science Newsletter September Edition

The 1 year anniversary edition of Liftstream’s monthly newsletter contains: >     Finance, funding and industry news including the injection of £25m into UK regenerative medicine research and Syndax pharma raising $26.6m in series B funding for their epigenetic … Continue reading

Posted in Pharmaceutical business | Leave a comment

Academic and industry partnerships drive new Gene Therapy push

Authored by James Sheppard There are many areas of pharmaceutical innovation currently receiving considerable attention, both for their scientific potential in a personalised medicine era but equally because of the potential they offer to investors. Gene Therapy is one such … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Onyx deal signals broader interest in orphan drugs

Authored by Karl Simpson The opportunities for orphan drug therapies addressing rare diseases has been a dominant feature of the pharmaceutical industry the past 12 months, and the fervour around companies working in the orphan drug category have been receiving … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

BioMerieux completes purchase of BioFire

Authored by James Sheppard The French diagnostic company BioMerieux has completed the purchase of US diagnostic company BioFire Diagnostics for $450m plus BioFire’s net financial debt. The deal is aimed at consolidating BioMerieux’s position as a major player in the … Continue reading

Posted in M&A Finance and Funding, Pharmaceutical business | Tagged , , , , , , , , , , | Leave a comment

Biogen and Isis cement alliance with new $100m pact

Authored by James Sheppard Biogen IDEC and Isis pharmaceuticals have agreed a partnership to advance the treatment of neurological diseases with antisense technology. This is not the first time that Biogen IDEC and Isis have teamed up. This is the … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , , , , | Leave a comment

UK aiming to boost regenerative medicine

Authored by James Sheppard Three of the UK’s leading research councils have pledged £25m to help kick start the regenerative medicine field in the UK. The funding will be used to provide equipment and research for regenerative medicine in a … Continue reading

Posted in M&A Finance and Funding | Tagged , , , , , , , , , , , , , , , , , , , | Leave a comment

DRI Capital raises third fund for royalty investments

Authored by Karl Simpson Royalties for pharmaceutical and biotech products is a constant feature of the way in which programmes get funded and investors get a return. The opportunity to cash in on a multi-year commercial return for a product … Continue reading

Posted in M&A Finance and Funding | Tagged , , , , , , , , , , , , , , , , , , , , | Leave a comment

Novartis Transplants itself into Stem Cell Therapy

Authored by James Sheppard The Swiss pharmaceutical giant Novartis has signalled its intent to play a more active part in the burgeoning stem cell field with its recent partnering deal. Novartis has signed a deal with the US biotech Regenerex. … Continue reading

Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , | Leave a comment




Contact Us

   Liftstream Ltd.
67 Grosvenor Street
London
W1K 3JN

   Tel: ​+44 (0)20 3178 5864
   info@liftstream.com

Register your CV

Apply for sector specific vacancies or request a confidential discussion



Registered in England No: 5009233
VAT: 843679292

Follow Us





Sitemap